SCP
GSK icon

Stamos Capital Partners’s GSK GSK Stock Holding History

Stamos Capital Partners’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.01M Buy
114,724
+16,469
+17% +$871K 0.92% 36
2026
Q1 		$5.42M Sell
98,255
-21,928
-18% -$1.19M 0.85% 35
2025
Q4 		$5.89M Sell
120,183
-17,051
-12% -$795K 0.95% 28
2025
Q3 		$5.92M Sell
137,234
-48,758
-26% -$1.9M 1.12% 23
2025
Q2 		$7.14M Buy
185,992
+40,613
+28% +$1.55M 1.28% 19
2025
Q1 		$5.63M Sell
145,379
-149,441
-51% -$5.47M 1.47% 12
2024
Q4 		$9.97M Buy
294,820
+87,630
+42% +$3.15M 2.34% 8
2024
Q3 		$8.47M Buy
207,190
+16,710
+9% +$684K 1.99% 8
2024
Q2 		$7.33M Sell
190,480
-470
-0.2% -$19.8K 1.56% 11
2024
Q1 		$8.19M Buy
190,950
+19,780
+12% +$816K 1.86% 10
2023
Q4 		$6.34M Buy
171,170
+67,660
+65% +$2.43M 1.72% 14
2023
Q3 		$3.75M Buy
103,510
+9,740
+10% +$346K 0.84% 28
2023
Q2 		$3.34M Buy
+93,770
New +$3.36M 0.78% 37
2022
Q4 		– Sell
-68,530
Closed -$2.02M – 150
2022
Q3 		$2.02M Sell
68,530
-85,870
-56% -$3.25M 0.51% 51
2022
Q2 		$8.4M Hold
154,400
– – 2.54% 15
2022
Q1 		$8.41M Buy
154,400
+45,760
+42% +$2.49M 2.81% 11
2021
Q4 		$5.99M Buy
108,640
+25,128
+30% +$1.31M 2.78% 13
2021
Q3 		$3.99M Hold
83,512
– – 2.23% 22
2021
Q2 		$4.16M Sell
83,512
-1,048
-1% -$50.4K 2.19% 21
2021
Q1 		$3.77M Hold
84,560
– – 1.9% 25
2020
Q4 		$3.89M Buy
+84,560
New +$3.88M 1.66% 22
2020
Q2 		– Sell
-21,822
Closed -$1.03M – 73
2020
Q1 		$1.03M Buy
+21,822
New +$1.16M 0.54% 55
2019
Q3 		– Sell
-4,800
Closed -$243K – 48
2019
Q2 		$243K Sell
4,800
-5,600
-54% -$281K 0.24% 51
2019
Q1 		$525K Sell
10,400
-10,400
-50% -$520K 0.67% 42
2018
Q4 		$993K Buy
+20,800
New +$1.02M 0.75% 42

Other funds holding GSK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Stamos Capital Partners's GSK Position: Q2 2026 in Review

Stamos Capital Partners increased its GSK (GSK) stake by 17% in Q2 2026, buying an estimated $871K and bringing the position to 114,724 shares worth $6.01M. The position accounts for 0.92% of the portfolio, ranked #36.

Stamos Capital Partners first reported a position in GSK in Q4 2018 and has held it in 25 quarters since. The position peaked at $9.97M in Q4 2024. 1,042 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

  • Stamos Capital Partners held 114,724 shares of GSK worth $6.01M as of Q2 2026.
  • Stamos Capital Partners bought 16,469 GSK shares in Q2 2026, an estimated $871K.
  • GSK made up 0.92% of Stamos Capital Partners's portfolio in Q2 2026, its #36 holding.
  • Stamos Capital Partners first reported a position in GSK in Q4 2018 and has held it in 25 quarters since.
  • Stamos Capital Partners's GSK position peaked at $9.97M in Q4 2024.
  • 1,042 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Stamos Capital Partners's 13F filing for Q2 2026, filed 13 Aug 2026.